Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

48.90EUR
18 Apr 2019
Change (% chg)

€-0.32 (-0.65%)
Prev Close
€49.22
Open
€49.24
Day's High
€49.60
Day's Low
€48.37
Volume
2,463,671
Avg. Vol
2,014,793
52-wk High
€71.36
52-wk Low
€38.28

Select another date:

Thu, Apr 11 2019

Photo

Fresenius may not be ideal owner for some business activities: CEO

DUESSELDORF, Germany German healthcare group Fresenius is happy with its current portfolio but may consider selling some non-core business activities within its units, its chief executive told an association of business journalists on Wednesday evening.

Fresenius may not be ideal owner for some business activities -CEO

DUESSELDORF, Germany, April 11 German healthcare group Fresenius is happy with its current portfolio but may consider selling some non-core business activities within its units, its chief executive told an association of business journalists on Wednesday evening.

Fresenius flags faster earnings growth from 2020 after investment

BERLIN Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday.

UPDATE 2-Fresenius flags faster earnings growth from 2020 after investment

* Announces 1 bln euros share buyback at Fresenius Medical Care

Fresenius expects earnings to stagnate in 2019 as investments weigh

BERLIN, Feb 20 German healthcare group Fresenius said sales growth would slow and profit stagnate this year as investments to fix the performance at its German hospitals business and build up home dialysis take a toll.

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

UPDATE 2-Fresenius plunges as health firm warns investment to hit profit

* Shares plunge 18 percent, poised for biggest one-day drop (Adds analyst comment, loss in market value)

Fresenius cuts guidance, vows further dividend hikes

FRANKFURT, Dec 7 German healthcare group Fresenius cut its medium-term guidance late on Thursday hurt by lower profit expectations at its dialysis arm FMC and its clinics chain Helios but said that dividends will continue to grow.

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

Fresenius says working to fix performance at dialysis business, German hospitals

BERLIN Germany's Fresenius said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

Select another date: